ArticleLung2012
Improvements in cystic fibrosis lung disease and airway inflammation associated with etanercept therapy for rheumatoid arthritis: a case report.
Article in Lung, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Case Report: TRNT1 related autoinflammatory syndrome in a patient with primary ciliary dyskinesia.Frontiers in immunology · 2026Article
- Arthritis in Cystic Fibrosis-Comparison of a Single-Center Cohort and Published Case Reports/Series and a Review of the Literature.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Review
- Article
- TNFRSF1B Signaling Blockade Protects Airway Epithelial Cells from Oxidative Stress.Antioxidants (Basel, Switzerland) · 2024Article
- Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis.Journal of clinical medicine · 2023Article
- Rheumatoid arthritis in a patient with cystic fibrosis: challenging treatment options.BMJ case reports · 2020Article
- Predominant pathogen competition and core microbiota divergence in chronic airway infection.The ISME journal · 2015Article
- Disrupted tight junctions in the small intestine of cystic fibrosis mice.Cell and tissue research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) lung pathology is characterized by excessive neutrophilic inflammation and high tumor necrosis factor-alpha (TNF-α) levels. A cornerstone of CF management is reduction of the inflammatory burden in the lung. We present the case of a 19-year-old CF patient who demonstrated significant clinical improvement in her lung disease associated with a reduction in sputum percent neutrophils, following commencement of etanercept (TNF-α antagonist) for rheumatoid arthritis. She has not had any infectious complications or other significant adverse effects during 2 years of treatment. It may be time to reconsider TNF-α antagonists as potential anti-inflammatory agents for CF lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.